PLUS THERAPEUTICS, INC. 8-K

What Happened

• On Feb 13, 2026, Plus Therapeutics, Inc. (PSTV) filed a Current Report on Form 8-K referencing its Registration Statement on Form S-1 (File No. 333-292637) originally filed Jan 9, 2026. The S-1’s Summary Compensation Table for 2025 and 2024 noted the Compensation Committee had not yet determined discretionary cash bonuses for the company’s principal executive officer and up to two of the most highly compensated executive officers for the fiscal year ended December 31, 2025. The filing states those bonus amounts will be disclosed in a separate Form 8-K.

Key Details

• S-1 filing date: January 9, 2026 (File No. 333-292637).
• Fiscal year referenced: Year ended December 31, 2025.
• Subject: Discretionary cash bonuses for the principal executive officer and up to two other Named Executive Officers had not been determined at time of the S-1.
• Next step: The specific bonus amounts are to be reported in a subsequent Form 8‑K.

Why It Matters

• Executive bonus amounts affect executive pay disclosure and can influence assessments of corporate governance and total compensation expense.
• Investors do not yet have the dollar values for 2025 discretionary bonuses; expect a follow-up Form 8‑K that will provide the actual amounts and complete the 2025 compensation picture.